Skip to main content
. 2021 Oct 20;13(11):1750. doi: 10.3390/pharmaceutics13111750

Figure 3.

Figure 3

Morphological assessment of the nasal MucilAir™ in vitro models treated repeatedly with undiluted mometasone or placebo nasal spray, culture medium treated or untreated using phase-contrast microscopy. The apical surface view is shown. Cell shedding is observed in the undiluted mometasone- and placebo-treated nasal MucilAir™ in vitro models, which starts at the periphery on day 7 (inserts). Cell detachment is almost complete on day 11. Asterisks indicate areas without cells; arrows indicate the remaining cells on the growth surface. Scale bars, 100 µm.